TP53 and cancer: The potentially clinically significant finding was that p53γ expression allowed discrimination between two subpopulations of patients bearing mutant p53 tumours: (1) patients bearing mutant p53 cancer and expressing p53γ who had disease-free survival and overall survival as good as patients with wild-type p53 and (2) patients bearing mutant p53 tumours without detectable p53γ isoform expression who had a particularly poor prognosis.